Open Orphan PLC - London-based pharmaceutical services contract research company - Signs a contract renewal until the end of 2021 with a pharmaceutical client. Does not disclose identity of client but says it its a major top-3 global pharmaceutical company. Under the contract, the Venn Life Sciences team will provide chemistry, manufacturing & control consultancy services to the client.
"Venn have been providing CMC support to this top tier company since 2012 and are pleased to be continuing to work with this client in their vaccine development programme," says Open Orphan Chair Cathal Friel.
Current stock price: 26.89 pence
Year-to-date change: up 4.2%
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.